[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Article
March 2003

Percutaneous Isolated Hepatic Perfusion for Chemotherapy: A Phase 1 Study

Author Affiliations

From the Centre H[[eacute]]pato-Biliaire, H[[ocirc]]pital Paul Brousse, Assistance Publique[[ndash]]H[[ocirc]]pitaux de Paris, Universit[[eacute]] Paris Sud, Villejuif, France (Drs Savier, Azoulay, Huguet, Gil-Delgado, and Bismuth); and the Laboratoire de Pharmacologie Clinique, Centre Ren[[eacute]] Hugenin, Saint-Cloud, France (Dr Lokiec).

Arch Surg. 2003;138(3):325-332. doi:10.1001/archsurg.138.3.325

Background  Increasing the drug concentration in tumors may produce massive tumoral response. By using a variety of hepatic vascular isolation techniques, high concentrations of chemotherapeutic drugs may be achieved in the hepatic vascular bed.

Hypothesis  Complete percutaneous isolated hepatic perfusion (IHP) is feasible and safe.

Design  Case series.

Setting  The hepatobiliary unit of a university hospital.

Patients  Ten patients with irresectable and chemoresistant hepatic tumors were eligible for study participation; 4 patients with hepatic metastases of breast cancer, gastric cancer, colorectal cancer, and cholangiocarcinoma were included.

Intervention  Patients received 3 successive courses of chemotherapy by IHP. The first course was given at laparotomy, and the next 2 courses were given percutaneously. The interval between courses was 3 to 6 weeks. Each course involved IHP of the liver for 15 to 30 minutes, without oxygenation, with 1 to 3 boluses of melphalan (15 mg).

Main Outcome Measures  Morbidity and mortality.

Results  Ten IHPs were performed (4 at laparotomy and 6 percutaneously). Concentrations of melphalan in the extracorporeal circulation were 10 times higher than those in the systemic circulation. Percutaneous IHPs had more leakage than those at laparotomy. However, hepatotoxicity was minimized. One patient experienced hepatic artery thrombosis, and 3 had severe neutropenia. Minor complications included ascites and pleural effusion. No deaths were observed 2 months after the last IHP. One partial response was observed (hepatic metastases of breast cancer).

Conclusion  Percutaneous IHP for intensive chemotherapy is less aggressive and less hepatotoxic than IHP at laparotomy and may be iterative.